Animal models of lean metabolic dysfunction-associated steatotic liver disease (MASLD): bridging pathogenesis and novel drug discovery

Lean MASLD is mechanistically distinct from obesity-related MASLD. Animal models have advanced our understanding of their unique drivers, including bile acid dysregulation, leptin signaling, and oxidative stress. These insights may guide the development of targeted therapies tailored to lean patients and improve clinical outcomes through individualized approaches.

Authors

Eva N. Kassi (ORCID: https://orcid.org/0000-0001-7491-2297)
Antonios Chatzigeorgiou (ORCID: https://orcid.org/0000-0002-7039-4223)
Rallia-Iliana Velliou (ORCID: https://orcid.org/0000-0001-6249-2504)
Stavros P. Papadakos (ORCID: https://orcid.org/0000-0003-1583-1125)
Chara Georgiadou

Institutions

National and Kapodistrian University of Athens (GR)
Laiko General Hospital of Athens (GR)

Publication Details

Journal: Expert Opinion on Drug Discovery
Published: 2025-10-24
DOI: https://doi.org/10.1080/17460441.2025.2579124
Citations: 1
Primary Topic: Liver Disease Diagnosis and Treatment
Type: article
Field-Weighted Citation Impact: 1.35

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Animal models of lean metabolic dysfunction-associated steatotic liver disease (MASLD): bridging pathogenesis and novel drug discovery

Eva N. Kassi, Antonios Chatzigeorgiou, Rallia-Iliana Velliou, Stavros P. Papadakos et al.

Oct 24, 2025

1 citations

Expert Opinion on Drug Discovery

Liver Disease Diagnosis and Treatment

1.35

article

Animal models of lean metabolic dysfunction-associated steatotic liver disease (MASLD): bridging pathogenesis and novel drug discovery

Eva N. Kassi, Antonios Chatzigeorgiou, Rallia-Iliana Velliou, Stavros P. Papadakos, Chara Georgiadou

October 24, 2025article en

1 citations

Abstract

Lean MASLD is mechanistically distinct from obesity-related MASLD. Animal models have advanced our understanding of their unique drivers, including bile acid dysregulation, leptin signaling, and oxidative stress. These insights may guide the development of targeted therapies tailored to lean patients and improve clinical outcomes through individualized approaches.

Expert Opinion on Drug DiscoveryVol. 20(12)

National and Kapodistrian University of Athens (GR), Laiko General Hospital of Athens (GR)

Openalex Percentile: Top 14%

Liver Disease Diagnosis and Treatment

1.35

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Animal models of lean metabolic dysfunction-associated steatotic liver disease (MASLD): bridging pathogenesis and novel drug discovery — Eva N. Kassi, Antonios Chatzigeorgiou, et al. · Expert Opinion on Drug Discovery (2025) | TGRS Research Map | TGRS